Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 16 February 2018
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
 
This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2015 under the GlaxoSmithKline Performance Share Plan ('PSP'), which were subject to relevant business performance conditions.  The three-year performance period for the 2015 awards commenced on 1 January 2015 and ended on 31 December 2017. 
 
The performance measure vesting details for those Persons Discharging Managerial Responsibilities ('PDMRs') who received awards in 2015 are set out in the following table. 
 
 
Outcome and Vesting Level
 
Portion of the Award
 
Measure and Outcome
 
% of maximum
 
% of award
 
1/3rd
 
Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £12.47bn which is above the threshold level of £11.48bn.
 
63
 
21
 
1/3rd
 
Total Shareholder Return - For the three years ending 31 December 2017, the Company's Total Shareholder Return ranked 5th, which is above the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.
 
44
 
14.67
 
1/3rd
 
R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £11.266bn, which is above the maximum vesting level of £7.912bn (the threshold level was £6.474bn). 
 
100
 
33.33
 
 
Total vesting for 2015 award
Lapsed
69%
31%
 
 
The notifications that follow are for awards made to PDMRs and detail the PSP conditional awards that vested, including dividends accrued, on 15 February 2018.  The balance of the award made to each PDMR has lapsed.
 
The closing share prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 15 February 2018 were £13.004 and $37.31.
 
 
 
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
91,430
£0.00
47,391
d)
Aggregated information
 
Aggregated volume
 
Price
 
 
138,821
 
£0.00
 
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
71,160
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
18,203
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.  These shares are subject to a two-year holding period to end in 2020.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
154,763
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan. 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
34,502
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
b)
Nature of the transaction
The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan and which were made to compensate for the value of awards forfeited on completion of the Joint Venture with Novartis.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$0.00
24,345
$0.00
4,871
d)
Aggregated information
 
Aggregated volume
 
Price
 
 
29,216
 
$0.00
 
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
56,605
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
75,473
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
43,667
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$0.00
66,334
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P Vallance
b)
Position/status
Outgoing President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
156,984
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each 'Ordinary Shares'
ISIN: GB0009252882
 
 
b)
Nature of the transaction
The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.00
9,667
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2018-02-15
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 16, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc